Sedana Medical Q3: A blow but no curtains-down event
Research Update
2024-10-28
16:32
Redeye lowers its fair value range following a reconsideration of its financial estimates (following the shifted US launch timeline) and an increased WACC. We argue that investor interest in the share is bound to be low for some time, but its long-term US prospects are still intriguing.
Oscar Bergman
Disclosures and disclaimers